Parplus Partners’s Elevance Health ELV Stock Holding History

Parplus Partners’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,066	Closed	-$322K	–	53
2019 Q4	$322K	Buy	+1,066	New	+$293K	0.06%	113

Other funds holding ELV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parplus Partners's ELV Position: Q1 2020 in Review

Parplus Partners sold out of Elevance Health (ELV) in Q1 2020, closing a stake of 1,066 shares — an estimated $322K sold.

Parplus Partners first reported a position in ELV in Q4 2019 and held it in 1 quarter. The position peaked at $322K in Q4 2019. 1,051 funds tracked by Wall St. Rank hold ELV as of Q1 2020.

Parplus Partners reported no remaining Elevance Health position as of Q1 2020 after selling out during the quarter.
Parplus Partners sold 1,066 Elevance Health shares in Q1 2020, an estimated $322K.
Parplus Partners first reported a position in Elevance Health in Q4 2019 and held it in 1 quarter.
Parplus Partners's Elevance Health position peaked at $322K in Q4 2019.
1,051 funds tracked by Wall St. Rank held Elevance Health as of Q1 2020.

Based on Parplus Partners's 13F filing for Q1 2020, filed 14 May 2020.